Sabine Vogler - Gesundheit Österreich GmbH (Austrian Public Health Institute, GÖG)
Dr Sabine Vogler is Head of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies affiliated to the Department at the Austrian Public Health Institute. She is senior researcher and Head of the Pharmacoeconomics Department. Sabine Vogler has expertise and in-depth knowledge about European countries with regard to pharmaceutical pricing/prices, reimbursement and distribution, as well as cost-containment reforms, access and affordability issues. She is/was the principal investigator of large projects including the PPRI (Pharmaceutical Pricing and Reimbursement Information) project, the PHIS (Pharmaceutical Health Information System) project and a Study on enhanced cross-country coordination in the area of pharmaceutical product pricing, and she manages the on-going PPRI network. She published several articles, studies and reports. Before joining the Austrian Health Institute in 1995, Dr. Vogler worked at the Department of Social Policies at the Vienna University of Business Administration and Economics where she obtained her PhD for her thesis on care for elderly people.
Hanne Bak Pedersen - WHO, Regional Office for Europe
Hanne Bak Pedersen is programme manager for health technologies and pharmaceuticals at the Division of Health Systems and Public health at the WHO Regional Office for Europe. Her topics of Interest are rational pharmacotherapy, systems for valuation of health technology, HTA, medicines for children, improving access to essential medicines and health technologies and user perspectives. Before, Hanne Bak Pedersen worked in the UNICEF Supply Division.
Nina Zimmermann - Gesundheit Österreich GmbH (Austrian Public Health Institute, GÖG)
Nina Zimmermann works for the of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies affiliated to the Pharmacoeconomics Department at the Austrian Public Health Institute. She has been working for the secretariat of the PPRI network (http://whocc.goeg.at/Networks/Organisation) at the Austrian Public Health Institute since 2009. Ms. Zimmermann was a key researcher in - to- major EU projects on pharma-economic issues (PPRI, PHIS) and other relevant projects at (inter-)national level in the pharmaceutical field (e.g. Pharma Policy Mix 2013). She organized the last PPRI Conference in 2011 in Vienna. She has experience in international, national and regional research of pharmaceutical systems and pharmaceutical policy analysis in the EU Member States. Nina Zimmermann has a master’s degree in Health Management from the University of Applied Science Krems, Austria. Furthermore she completed a master course on ‘European studies - Management of EU projects’ at the University of Applied Science Eisenstadt, Austria. She has also gained previously working experience in the fields of injury prevention and addiction prevention as well as international cooperation and research projects.
Peter Schneider - Gesundheit Österreich GmbH (Austrian Public Health Institute, GÖG)
Peter Schneider holds a degree in Economics and a Master degree in Economics of International Trade and European Integration. He is involved in the PPI (Pharma Price Information) team, the European medicine price database EURIPID project, WHO Collaborating Centre and ongoing projects in the Austrian health care reform process. He is also member of the Austrian Health Economics Association (ATHEA). His research areas are pricing and reimbursement of pharmaceuticals, analysis and comparison of health and pharmaceutical systems, health economics and pharmacoeconomics.
Peter Beyer - WHO Headquarter
Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization in Geneva where he is responsible for issues related to public health, trade and intellectual property. This includes work on innovative funding mechanisms for research and development. Peter was instrumental in setting up a sustainable cooperation among the World Intellectual Property Organization, the World Trade Organization and WHO as well as the WHO/DNDi initiative on a Global Partnership for Antibiotic R&D. He is also responsible for the development of a global development and stewardship framework for antimicrobial resistance. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and headed negotiations at WHO and WIPO. Furthermore, he was responsible for the bilateral dialogue between Switzerland and China on intellectual property.
Guillaume Dedet - WHO, Regional Office for Europe
Guillaume Dedet is a public health physician trained in Paris with a significant academic background in statistics (Université Paris Sud) and health economics (London School of Economics). His main areas of interest cover health technology assessment and pharmaceutical pricing policies. He is currently a technical officer in the Health Technologies and Pharmaceuticals unit at the WHO regional office for Europe. Prior joining WHO, Guillaume Dedet served as the medical advisor in the pharmaceuticals pricing and reimbursement department at the French Ministry of Health.
Roberta Joppi - Local Health Authority of Verona, Veneto Region, Italy
Roberta Joppi is a Clinical Pharmacist. She got her Chem Pharm degree, the specialisation in Clinical Pharmacy and a Master in Systematic Reviews at the Milan University. She worked at the Pharmacy Department of the following Hospitals: Regional Hospital in Bolzano, Regional Hospital in Rovigo, University Hospital in Verona. At present she is Head of the Clinical Research & Drug Assessment Unit – Pharma Department of the Local Health Authority in Verona and visiting Scientist at the Laboratory of Drug Regulatory Policies of the ‘Mario Negri’ Institute in Milan. She is responsible for the Italian Horizon Scanning Project, chair of the EuroScan International Network, member of the Steering Group of the WP8 on Development of a risk-adapted monitoring toolbox of the EU-ECRIN project and member of the Piperska Group. Her main areas of interest have been drug assessment, epidemiology of interventions, clinical trials and drug utilisation studies in the cardiovascular and psychiatric areas.